Transfer of USP Methods for Impurities Analysis of Ziprasidone HCl between HPLC Systems and to UPLC

Importance of the topic

The transfer of compendial chromatographic methods between different instrument platforms is critical for maintaining consistent quality control across pharmaceutical laboratories. Ziprasidone HCl impurity analysis is a key assay in product release and stability testing, requiring robust methodology to ensure regulatory compliance and reliable results.

Objectives and Study Overview

This study aimed to demonstrate the seamless transfer of two United States Pharmacopeia (USP) impurity methods for ziprasidone HCl—targeting early- and late-eluting impurities—from legacy HPLC systems to modern UPLC technology. In addition, a lab-to-lab reproducibility assessment was conducted to validate method consistency across geographical sites.

Methodology and Instrumental Setup

Sample solutions were prepared using a methanol/water/concentrated HCl diluent (20:5:0.01), as specified by the USP monograph, with additional filtration through 0.2 µm PTFE membranes. HPLC analyses employed an XBridge C8 column (4.6 × 150 mm, 5 µm) under isocratic conditions at 229 nm, while UPLC conversions used an ACQUITY UPLC BEH C8 column (2.1 × 50 mm, 1.7 µm). Key method adjustments included evaluating injection volume, sample diluent composition, and post-injector system volume to address peak distortion due to strong solvent effects.

Instrumental Setup

• Alliance 2695 HPLC with 2489 UV/Visible Detector
• ACQUITY UPLC H-Class System with TUV Detector
• XBridge HPLC Columns and ACQUITY UPLC BEH C8 Columns
• Empower 3 Software and Method Transfer Kits

Main Results and Discussion

Migration to a low-volume UPLC system initially resulted in peak fronting when injecting samples dissolved in 80% methanol. Optimization experiments revealed that increasing the post-injector volume with 50 µL tubing effectively mitigated distortion and restored peak symmetry without modifying USP-specified diluent composition or excessive reduction of injection volume. Subsequent method transfer achieved:

• Consistent system suitability metrics (resolution ≥ 1.5 for early, ≥ 6.0 for late impurities; RSD ≤ 10%).
• Run time reductions of 63% (early impurities) and 58% (late impurities) using UPLC.
• Mobile phase consumption savings of 93% per injection.
• Successful cross-validation between Waters laboratories in the USA and France with comparable results.

Benefits and Practical Applications

Implementing UPLC for USP compendial methods enhances laboratory throughput and reduces solvent costs and waste disposal fees. The ACQUITY UPLC H-Class platform supports both HPLC and UPLC workflows on a single system, streamlining asset utilization and minimizing the need for separate instrumentation.

Future Trends and Applications

Advancements may include integrating automated method transfer software, expanding green analytical chemistry approaches with alternative solvents, and applying similar transfer strategies to other pharmacopeial assays. The combination of UPLC with digitalization and AI-driven optimization is expected to further accelerate method development and regulatory compliance.

Conclusion

The study confirms that USP impurity methods for ziprasidone HCl can be reliably transferred from conventional HPLC systems to UPLC with minimal adjustments. The UPLC methods maintain compendial requirements, deliver significant reductions in analysis time and solvent use, and demonstrate reproducible performance across different laboratories.

References

• USP Monograph, Ziprasidone HCl, USP35-NF29, The United States Pharmacopeia Convention, official May 1, 2012.
• USP General Chapter, <621> Chromatography, USP35-NF30, The United States Pharmacopeia Convention, official December 1, 2012.
• Jones MD, Alden P, Fountain KJ, Aubin A. Implementation of Methods Translation between Liquid Chromatography Instrumentation. Waters Application Note 720003721en, September 2010.